MB
AXSM icon

MPM BioImpact’s Axsome Therapeutics AXSM Stock Holding History

MPM BioImpact’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50,000
Closed -$4.23M – 47
2024
Q4 		$4.23M Buy
+50,000
New +$4.6M 0.6% 39
2024
Q3 		– Sell
-132,312
Closed -$10.7M – 47
2024
Q2 		$10.7M Buy
132,312
+18,185
+16% +$1.35M 1.66% 22
2024
Q1 		$9.11M Buy
114,127
+20,740
+22% +$1.74M 1.46% 25
2023
Q4 		$7.43M Sell
93,387
-199
-0.2% -$13.3K 1.74% 25
2023
Q3 		$6.54M Hold
93,586
– – 1.75% 21
2023
Q2 		$6.73M Buy
93,586
+23,184
+33% +$1.71M 1.35% 23
2023
Q1 		$4.34M Buy
70,402
+18,427
+35% +$1.21M 1.13% 23
2022
Q4 		$4.01M Buy
+51,975
New +$3.11M 1.04% 21
2022
Q2 		– Sell
-99,834
Closed -$4.13M – 39
2022
Q1 		$4.13M Sell
99,834
-3,571
-3% -$111K 1.11% 25
2021
Q4 		$3.91M Sell
103,405
-6,750
-6% -$248K 0.71% 27
2021
Q3 		$3.63M Buy
+110,155
New +$4.29M 0.56% 32

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

MPM BioImpact's AXSM Position: Q1 2025 in Review

MPM BioImpact sold out of Axsome Therapeutics (AXSM) in Q1 2025, closing a stake of 50,000 shares — an estimated $4.23M sold.

MPM BioImpact first reported a position in AXSM in Q3 2021 and held it in 11 quarters. The position peaked at $10.7M in Q2 2024. 352 funds tracked by Wall St. Rank hold AXSM as of Q1 2025.

  • MPM BioImpact reported no remaining Axsome Therapeutics position as of Q1 2025 after selling out during the quarter.
  • MPM BioImpact sold 50,000 Axsome Therapeutics shares in Q1 2025, an estimated $4.23M.
  • MPM BioImpact first reported a position in Axsome Therapeutics in Q3 2021 and held it in 11 quarters.
  • MPM BioImpact's Axsome Therapeutics position peaked at $10.7M in Q2 2024.
  • 352 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2025.

Based on MPM BioImpact's 13F filing for Q1 2025, filed 15 May 2025.